Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 13/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181255 | 0.96 | GRIN1 (0.40) | GRIN1GRIN2BHIF1AALDH1A1PCSK9 | |
| SCHEMBL2184529 | 0.90 | GRIN1 (0.43) | GRIN1GRIN2BHIF1AALDH1A1CYP1A2 | |
| SCHEMBL2181258 | 0.89 | HIF1A (0.39) | GRIN1GRIN2BHIF1AALDH1A1SMN1; SMN2 | |
| SCHEMBL2182212 | 0.88 | GRIN1 (0.44) | GRIN1GRIN2BHIF1AALDH1A1SMN1; SMN2 | |
| SCHEMBL2182702 | 0.88 | GRIN1 (0.42) | GRIN1GRIN2BHIF1AALDH1A1 | |
| SCHEMBL2181927 | 0.87 | GRIN1 (0.39) | GRIN1GRIN2BHIF1AALDH1A1CYP1A2 | |
| SCHEMBL2183539 | 0.87 | GRIN1 (0.41) | GRIN1GRIN2BHIF1AALDH1A1GAA | |
| SCHEMBL2182524 | 0.86 | HRH3 (0.40) | GRIN1GRIN2BHIF1AALDH1A1 | |
| SCHEMBL2184025 | 0.86 | PCSK9 (0.41) | GRIN1GRIN2BHIF1AALDH1A1PCSK9 | |
| SCHEMBL2181596 | 0.86 | GRIN1 (0.42) | GRIN1GRIN2BHIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | GRIN1 4764/4885GRIN2B 3116/4885HIF1A 1000/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | GRIN1 2564/4885GRIN2B 2081/4885HIF1A 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.